Actively Recruiting

Phase 2
Phase 3
Age: 1Year - 18Years
All Genders
NCT06673290

Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations

Led by West China Hospital · Updated on 2024-12-31

150

Participants Needed

1

Research Sites

108 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to compare the efficacy and safety of different concentration gradients of sirolimus in the treatment of cystic lymphatic malformation.

CONDITIONS

Official Title

Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations

Who Can Participate

Age: 1Year - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female patients
  • Between 0 and 18 years of age
  • Confirmed diagnosis of lymphatic malformation by biopsy, compatible MRI findings, history, and clinical features as agreed by local investigators and a multidisciplinary vascular anomaly group
Not Eligible

You will not qualify if you...

  • Allergy or contraindication to sirolimus or related drugs
  • Use of chemotherapy, embolization, corticosteroids, propranolol, sclerotherapy, or other investigational agents within 1 week before study enrollment
  • Major surgery within 2 weeks before enrollment
  • Previous treatment with sirolimus or other mTOR inhibitors
  • Evidence of significant local or systemic uncontrolled infection requiring intravenous antibiotics at enrollment
  • Severe or uncontrolled medical diseases that could affect study participation, such as uncontrolled diabetes, hypertension, severe malnutrition, chronic liver or kidney disease, or active upper gastrointestinal ulcers
  • Gastrointestinal dysfunction or chronic disease that may affect sirolimus absorption
  • Inadequate liver function (total bilirubin ≥1.5 times upper limit of normal for age; alanine aminotransferase and aspartate aminotransferase ≥2.5 times upper limit of normal for age)
  • Inadequate renal function based on age-specific serum creatinine thresholds
  • Low bone marrow function (absolute neutrophil count below 1 × 10^9/L)
  • History of malignancy within 5 years
  • HIV infection or known immunodeficiency
  • Need for corticosteroids, vincristine, interferon-alpha, sirolimus, or tacrolimus for other conditions
  • Inability to participate in or comply with study treatment and assessments
  • Inability to provide informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

West China Hospital of Sichuan University

Chengdu, Sichuan, China, 610041

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here